Abstract
Objective: Olaparib (50-mg hard capsules) has been approved in the European Union since December 2014 as monotherapy for maintenance treatment of adult patients with platinum-sensitive relapsed BRCA-mutated ovarian cancer (PSR-OC) who are in response to platinum-based chemotherapy. Subsequently, film-coated tablets (100/150 mg) were approved in the European Union in May 2018, but regardless of BRCA status. So far, no real-world olaparib treatment data from patients who switched from olaparib hard capsules to film-coated tablets (switcher) are available.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
